Michael Nebozhyn

12.4k total citations · 1 hit paper
62 papers, 5.1k citations indexed

About

Michael Nebozhyn is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Michael Nebozhyn has authored 62 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 23 papers in Cancer Research and 14 papers in Molecular Biology. Recurrent topics in Michael Nebozhyn's work include Cancer Immunotherapy and Biomarkers (20 papers), Colorectal Cancer Treatments and Studies (15 papers) and Cancer Genomics and Diagnostics (14 papers). Michael Nebozhyn is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Colorectal Cancer Treatments and Studies (15 papers) and Cancer Genomics and Diagnostics (14 papers). Michael Nebozhyn collaborates with scholars based in United States, United Kingdom and Spain. Michael Nebozhyn's co-authors include Andrey Loboda, Mark Ayers, Jared Lunceford, Andrew Albright, Erin Murphy, Jennifer H. Yearley, Antoni Ribas, Jonathan D. Cheng, Terrill K. McClanahan and Tanguy Y. Seiwert and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Michael Nebozhyn

60 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

2017 2.3k citations Mark Ayers, Jared Lunceford et al. profile →

Peers

Michael Nebozhyn

ONCOL

IMMUN

PRM

Andrey Loboda United States

Tessa Fredriksen France

Takeshi Kuwata Japan

Christine Solbach Germany

James S. Wilmott Australia

Ravindra Uppaluri United States

Johan Botling Sweden

Noel F.C.C. de Miranda Netherlands

Michael S. Khodadoust United States

Eric A. Severson United States

Andrey Loboda United States

Michael Nebozhyn

3.6k ×1.2

ONCOL

1.9k ×1.2

IMMUN

2.3k ×1.4

1.4k ×1.3

PRM

1.1k ×1.1

Citations per year, relative to Michael Nebozhyn Michael Nebozhyn (= 1×) peers Andrey Loboda

Countries citing papers authored by Michael Nebozhyn

Since Specialization

Citations

This map shows the geographic impact of Michael Nebozhyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Nebozhyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Nebozhyn more than expected).

Fields of papers citing papers by Michael Nebozhyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Nebozhyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Nebozhyn. The network helps show where Michael Nebozhyn may publish in the future.

Co-authorship network of co-authors of Michael Nebozhyn

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Nebozhyn. A scholar is included among the top collaborators of Michael Nebozhyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Nebozhyn. Michael Nebozhyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Janjigian, Yelena Y., Michael Cecchini, Kohei Shitara, et al.. (2025). Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies. JCO Precision Oncology. 9(9). e2400456–e2400456. 1 indexed citations

Dent, Rebecca, Javier Cortés, Eva Muñoz‐Couselo, et al.. (2025). Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. Breast Cancer Research. 27(1). 35–35. 3 indexed citations

Yang, Mingli, Michael Nebozhyn, Michael J. Schell, et al.. (2025). Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer. BMC Cancer. 25(1). 441–441. 1 indexed citations

Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505. 8 indexed citations

Cortés, Javier, Oleg Lipatov, S-A. Im, et al.. (2023). 190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119. ESMO Open. 8(1). 101379–101379. 3 indexed citations

Shitara, Kohei, Maria Di Bartolomeo, Mario Mandalà, et al.. (2023). Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. Journal for ImmunoTherapy of Cancer. 11(6). e006920–e006920. 19 indexed citations

Cristescu, Răzvan, Michael Nebozhyn, Chunsheng Zhang, et al.. (2021). Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. Clinical Cancer Research. 28(8). 1680–1689. 40 indexed citations

Ayers, Mark, Michael Nebozhyn, Răzvan Cristescu, et al.. (2018). Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. Clinical Cancer Research. 25(5). 1564–1573. 27 indexed citations

Cook, Natalie, Bristi Basu, D. M. Smith, et al.. (2018). A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer. 118(6). 793–801. 96 indexed citations

10.

Guertin, Amy D., Jennifer O’Neil, Alexander Stoeck, et al.. (2016). High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide. Molecular Cancer Therapeutics. 15(8). 1998–2008. 16 indexed citations

11.

Schell, Michael J., Mingli Yang, Jamie K. Teer, et al.. (2016). A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nature Communications. 7(1). 11743–11743. 152 indexed citations

12.

Schell, Michael J., Mingli Yang, Edoardo Missiaglia, et al.. (2015). A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. Clinical Cancer Research. 22(3). 734–745. 30 indexed citations

13.

Sclafani, Francesco, Tae‐Yop Kim, David Cunningham, et al.. (2015). A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer. JNCI Journal of the National Cancer Institute. 107(12). djv258–djv258. 73 indexed citations

14.

Coppola, Domenico, Lodovico Balducci, Dung‐Tsa Chen, et al.. (2014). Senescence-associated-gene signature identifies genes linked to age, prognosis, and progression of human gliomas. Journal of Geriatric Oncology. 5(4). 389–399. 24 indexed citations

15.

Haines, Brian B., Michael J. Wick, Kyriakos P. Papadopoulos, et al.. (2012). Abstract 1868: Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma. Cancer Research. 72(8_Supplement). 1868–1868. 1 indexed citations

16.

Podtelezhnikov, Alexei A., Keith Q. Tanis, Michael Nebozhyn, et al.. (2011). Molecular Insights into the Pathogenesis of Alzheimer's Disease and Its Relationship to Normal Aging. PLoS ONE. 6(12). e29610–e29610. 58 indexed citations

17.

Galanis, Evanthia, Kurt A. Jaeckle, Matthew J. Maurer, et al.. (2009). Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology. 27(12). 2052–2058. 283 indexed citations

18.

Loboda, Andrey, Michael Nebozhyn, Chi‐Fung Cheng, et al.. (2009). Biomarker Discovery: Identification of a Growth Factor Gene Signature. Clinical Pharmacology & Therapeutics. 86(1). 92–96. 13 indexed citations

19.

Vachani, Anil, Michael Nebozhyn, Sunil Singhal, et al.. (2007). A 10-Gene Classifier for Distinguishing Head and Neck Squamous Cell Carcinoma and Lung Squamous Cell Carcinoma. Clinical Cancer Research. 13(10). 2905–2915. 50 indexed citations

20.

Virók, Dezső P., Andrey Loboda, Laszlo Kari, et al.. (2003). Infection of U937 Monocytic Cells withChlamydia pneumoniaeInduces Extensive Changes in Host Cell Gene Expression. The Journal of Infectious Diseases. 188(9). 1310–1321. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact